This company has been acquired
Peak Bio Past Earnings Performance
Past criteria checks 0/6
Peak Bio has been growing earnings at an average annual rate of 6.2%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 26.1% per year.
Key information
6.2%
Earnings growth rate
19.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -26.1% |
| Return on equity | n/a |
| Net Margin | -4,420.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Peak Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -3 | 6 | -1 |
| 30 Jun 24 | 0 | -5 | 6 | 0 |
| 31 Mar 24 | 0 | -8 | 7 | 0 |
| 31 Dec 23 | 0 | -13 | 8 | 0 |
| 30 Sep 23 | 1 | -19 | 12 | 0 |
| 30 Jun 23 | 0 | -21 | 11 | 0 |
| 31 Mar 23 | 1 | -18 | 11 | 0 |
| 31 Dec 22 | 1 | -13 | 9 | 0 |
| 30 Sep 22 | 0 | -8 | 4 | 0 |
| 30 Jun 22 | 0 | -8 | 4 | 0 |
| 31 Mar 22 | 1 | -8 | 3 | 0 |
| 31 Dec 21 | 1 | -8 | 2 | 0 |
Quality Earnings: PKBO is currently unprofitable.
Growing Profit Margin: PKBO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PKBO is unprofitable, but has reduced losses over the past 5 years at a rate of 6.2% per year.
Accelerating Growth: Unable to compare PKBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PKBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PKBO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.